| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

Core Insights - Minsheng Health reported a revenue of 641 million yuan for 2024, representing a year-on-year growth of 10.23% [1] - The company achieved a net profit attributable to shareholders of 91.83 million yuan, up 7.24% year-on-year [1] - Basic earnings per share stood at 0.26 yuan [1] Financial Performance - Gross margin for 2024 was 55.77%, a decrease of 6.30 percentage points year-on-year [3] - Net profit margin was 14.32%, a slight decline of 0.40 percentage points year-on-year [3] - Sales expenses amounted to 191 million yuan, an increase of 0.32% year-on-year, primarily for channel maintenance and brand promotion [3] - Research and development expenses were 23.98 million yuan, down 18.87% year-on-year, accounting for 3.74% of revenue [3] Cash Flow Analysis - Net cash flow from operating activities was 108 million yuan, a slight increase of 0.28% year-on-year, indicating stable operating cash collection ability [3] - Net cash outflow from investing activities was 280 million yuan, an increase of 45.53% year-on-year, mainly for fundraising projects and financial product purchases [3] - Net cash flow from financing activities was -38.34 million yuan, a decline of 104% year-on-year [3] Business Segmentation - Revenue from vitamins and minerals reached 621 million yuan, growing 10.47% year-on-year, accounting for 96.91% of total revenue [3] - Revenue from other health products was 12 million yuan, up 8.01% year-on-year, representing 1.93% of total revenue [3] - Probiotic revenue was 4.22 million yuan, down 33.74% year-on-year, making up 0.66% of total revenue [3] Research and Development - The company obtained 3 new authorized invention patents and completed the development of 5 functional food products in 2024 [3] - Ongoing research pipelines include Minoxidil lotion (for hair growth) and traditional Chinese medicine products, with future plans to expand into sleep health and sports nutrition sectors [3]

证券代码：301507 证券简称：民生健康 公告编号：2025-026 杭州民生健康药业股份有限公司 截至 2025 年 4 月 30 日，公司通过回购专用证券账户，以集中竞价交易方 式已累计回购股份 292,500 股，占公司当前总股本的 0.08%，最高成交价为 12.08 元/股，最低成交价为 11.83 元/股，支付金额为 3,503,018 元（不含交易费 用）。 重要内容提示： 回购方案的实施情况：截至 2025 年 4 月 30 日，杭州民生健康药业股份 有限公司（以下简称"公司"）通过回购专用证券账户，以集中竞价交易方式已 累计回购股份 292,500 股，占公司当前总股本的 0.08%，最高成交价为 12.08 元 /股，最低成交价为 11.83 元/股，支付金额为 3,503,018 元（不含交易费用）。 一、 回购股份的基本情况 公司于 2025 年 3 月 19 日召开第二届董事会第七次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司通过集中竞价交易方式以自 有资金回购部分社会公众股份，用于股权激励。回购价格不超过人民币 19.80 元 /股；预计回购股份数量为 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-025 杭州民生健康药业股份有限公司 关于举办 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）《2024 年年度报告》及 其摘要等相关文件已于 2025 年 4 月 25 日在巨潮资讯网（www.cninfo.com.cn）披 露。为便于广大投资者进一步了解公司的财务状况、经营情况及公司发展规划， 公司定于 2025 年 5 月 14 日（周三）15:00-16:30 在全景网举办 2024 年度网上业 绩说明会，本次业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投 资者关系互动平台"（https://ir.p5w.net）参与本次业绩说明会或者直接进入公司路 演厅（https://ir.p5w.net/c/301507.shtml）参与本次业绩说明会。 出席本次业绩说明会的人员有：公司董事长竺福江先生、总经理张海军先生、 财务负责人朱文君先生、独立董事刘玉龙先生、董事会秘书陈稳竹先生。（如有 特 ...

Financial Performance - The financial officer provided a detailed overview of the company's financial status for the full year 2024 and the first quarter of 2025, covering overall financial data, revenue composition, R&D investment, and operational capability indicators [1] - The company's gross profit margin fluctuated significantly on a quarterly basis, primarily influenced by the "opening red" effect in Q1, with expectations for stabilization as new products are launched [4] Market Overview and Strategic Planning - The general manager discussed the main market conditions over the past year and the business plans for the upcoming year, emphasizing the stability of the vitamin and mineral segment and the establishment of new product lines [1][2] - The company aims for diversified revenue sources through a richer product matrix and continuous optimization of the sales channel system [3] Product Development and Sales Channels - The company has established independent business units for new product development and operations, including the Medical Aesthetics Division and International Business Division, with two recently approved products expected to launch in Q3 [2] - The online sales share has seen significant growth, with future targets set for a reasonable proportion of online sales within the overall strategy [3] Cost and Taxation Considerations - The impact of tariffs on the company's operations is minimal, as the majority of business is focused on the domestic market, with only a small portion of imported reagents [5] - The sales performance of offline pharmacies has stabilized after initial policy and market environment impacts, with expectations for limited overall influence on the company [5] International Expansion Plans - The company plans to promote existing high-quality product categories to international markets, aiming to meet similar nutritional needs of overseas consumers [5] - There is also an intention to introduce mature foreign formulations to enhance product offerings through the company's brand and channel advantages [5] Meeting Summary - The board secretary concluded the online performance exchange meeting, expressing gratitude to the organizers and participating investment institutions [6]

Core Insights - Minsheng Health reported a revenue of 641 million yuan for 2024, marking a year-on-year growth of 10.23%, with a net profit of 91.83 million yuan, up 7.24% [1] - The company continues to show strong growth in Q1 2025, achieving a revenue of 271 million yuan, a 15.70% increase year-on-year [1] - The brand "21 Jin Weita" has solidified its position as a leading name in the mineral and vitamin sector, with product revenue surpassing 600 million yuan for the first time in 2024 [1][4] Financial Performance - For 2024, the company achieved a net cash flow from operating activities of 108 million yuan [1] - The first quarter of 2025 saw a net profit of 62.71 million yuan, reflecting a 6.51% increase compared to the same period last year [1] Research and Development - In 2024, the company invested 23.98 million yuan in R&D, accounting for 3.74% of its revenue [2] - The company and its subsidiaries obtained 1 new drug approval, 3 invention patents, and 4 utility model patents during the reporting period [2][5] Market Strategy - Minsheng Health is expanding its product matrix in the health sector, focusing on treatment OTC drugs and probiotics, in line with the "New Products, New Business, New Models, New Projects" strategy [3] - The company aims to enhance its core competitiveness in the health sector by exploring new areas such as gastrointestinal health, medical aesthetics, and smoking cessation [2][3] Brand Development - The brand "21 Jin Weita" has gained recognition, ranking among the top three brands in the Chinese market for multivitamins in 2024 [4] - The company is reviving the "Minsheng Tongchun" brand, which dates back to 1926, to cater to modern health needs [4] Industry Trends - The health product market in China is expected to grow significantly, with current consumption levels of dietary supplements being only one-fifth of those in developed countries [3] - The probiotics market is projected to grow at an annual rate of 11-12%, potentially reaching a market size of 137.7 billion yuan by 2026 [7] Strategic Partnerships - Minsheng Health signed a strategic cooperation agreement with Zhongke Jiayi to enhance its capabilities in the probiotics sector [7][8] - The partnership aims to develop a comprehensive probiotics platform, enhancing the company's market position and technical capabilities [8] Product Innovation - The company launched a new product "Jisuran" targeting the skin repair market, utilizing peptide technology [9] - A new liquid formulation of aluminum magnesium carbonate has been developed to meet the needs of younger consumers [9][10] Future Outlook - The company anticipates that the introduction of new products and business lines will lead to substantial growth in its operations [11]

Core Viewpoint - The company is experiencing growth in the health supplement market, driven by increasing health awareness and consumer demand for preventive healthcare products, leading to a strategic focus on product innovation and market expansion [3][5][19]. Company Overview - The company operates in the pharmaceutical manufacturing industry, specifically in the OTC (over-the-counter) drug and health supplement sectors, with its main product being the 21 Jinweita Multivitamin [3][4]. - The health supplement market in China is expanding, with significant growth potential compared to developed countries, as consumer awareness and demand for dietary supplements increase [4][7]. Industry Trends - The non-prescription drug market is benefiting from a shift towards preventive healthcare, supported by national policies promoting health awareness and consumer education [5][6]. - The aging population in China is driving demand for health management products, with a notable increase in the elderly demographic, which is expected to further boost the health supplement market [8][9]. Business Performance - The company reported a revenue of 641 million yuan, a year-on-year increase of 10.23%, and a net profit of 91.83 million yuan, up 7.24% from the previous year [19]. - The company is focusing on expanding its product matrix in the health supplement sector, enhancing its brand presence, and optimizing its sales channels to improve market competitiveness [10][14]. Product and Brand Strategy - The company has a diverse product range, primarily focusing on vitamins and minerals, and is committed to continuous research and development to meet varying consumer needs [11][12]. - The brand "21 Jinweita" has established itself as a leading name in the vitamin and mineral sector, with recognition in various industry awards and rankings [13]. Marketing and Sales Network - The company has developed a comprehensive marketing network, utilizing both online and offline channels to reach consumers effectively, including major e-commerce platforms [14]. - The company is adapting its sales strategies to align with changing consumer behaviors and preferences, ensuring broad market coverage [14]. Management and Innovation - The company boasts a professional management team with extensive experience in the health product sector, focusing on innovation and compliance with industry standards [15]. - The company has established a robust core technology system for product formulation and quality control, continuously improving its capabilities [16].

杭州民生健康药业股份有限公司 2024 年度内部控制评价报告 杭州民生健康药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求(以下简 称企业内部控制规范体系)，结合对杭州民生健康药业股份有限公司(以下简称公司或本公司) 内部控制制度和评价办法，在内部控制日常监督和专项监督的基础上，我们对公司2024年12 月31日(内部控制评价报告基准日)的内部控制有效性进行了评价。 一．重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并 如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行 监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容 的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真 实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅 能为实现上述目标提供合理保证。此外，由于情况的变化可能导致 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-019 杭州民生健康药业股份有限公司 关于公司及子公司使用自有资金进行现金管理 的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 在不影响日常经营资金需求并有效保障资金安全的前提下，公司及合并报表 范围内的下属子公司使用闲置自有资金适度开展现金管理，有利于提高公司资金 利用率，增加公司收益，最大化利用闲置资金。 杭州民生健康药业股份有限公司（以下简称"公司"）于2025年4月23日召 开第二届董事会第八次会议及第二届监事会第五次会议，分别审议通过了《关于 公司及子公司使用自有资金进行现金管理的议案》，同意公司及合并报表范围内 的下属子公司在最高额不超过人民币6.5亿元的额度内进行现金管理，有效期自 股东大会审议通过之日起12个月。在上述额度及有效期内，资金可循环滚动使用， 期限内任一时点的金额不应超过前述授权额度。该议案尚需提交股东大会审议。 现将具体情况公告如下： 一、现金管理概况 （二）现金管理额度及期限 （一）现金管理目的 公司及合并报表范围内的下属子公司拟在最高额不超过人民币 ...

证券代码：301507 证券简称：民生健康 公告编号：2024-017 杭州民生健康药业股份有限公司 2024 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何虚 假记载、误导性陈述或者重大遗漏。 根据中国证券监督管理委员会发布的《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求》和深圳证券交易所发布的《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定及相关格式指 引的要求，杭州民生健康药业股份有限公司（以下简称"公司"）就 2024 年度募集 资金存放与使用情况专项说明如下： 一、募集资金基本情况 (一) 实际募集资金金额、资金到账时间 二、募集资金管理情况 (一) 募集资金的管理情况 为规范募集资金的存放、管理和使用，提高募集资金使用效率和效益，保护投 资者利益，根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监 管要求》《深圳证券交易所创业板股票上市规则》及《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》等有关法律、法规和规范性文件 及公司《募集资金管理办法 ...